BIAF announces AU patent acceptance for lung health method

Rhea-AI Filing Summary

bioAffinity Technologies reported that the Australian Patent Office has accepted its patent application AU 2019253111, titled “System and Method for Determining Lung Health.” The patent covers methods that combine flow cytometry with fluorescent probes and molecular tags that attach to specific cell types to detect cellular and molecular signatures of multiple lung diseases. The company issued a press release, attached as Exhibit 99.1.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

false 0001712762 0001712762 2025-10-28 2025-10-28 0001712762 BIAF:CommonStockParValue0.007PerShareMember 2025-10-28 2025-10-28 0001712762 BIAF:WarrantsToPurchaseCommonStockMember 2025-10-28 2025-10-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 28, 2025

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41463		46-5211056
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

3300 Nacogdoches Road, Suite 216

San Antonio, Texas 78217

(Address of principal executive offices, including zip code)

(210) 698-5334

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Title of each class		Trading Symbols		Name of each exchange on which registered
Common Stock, par value $0.007 per share		BIAF		The Nasdaq Stock Market LLC (Nasdaq Capital Market)
Warrants to purchase Common Stock		BIAFW		The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On October 28, 2025, bioAffinity Technologies, Inc., a Delaware corporation, issued a press release announcing that the Australian Patent office has accepted its patent application AU 2019253111 titled “System and Method for Determining Lung Health,” which covers methods that use flow cytometry combined with fluorescent probes, molecular tags that attach to specific cell types, to detect cellular and molecular signatures of multiple lung diseases.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release issued by bioAffinity Technologies, Inc., dated October 28, 2025
104		Cover Page Interactive Data File (embedded within the XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 28, 2025	BIOAFFINITY TECHNOLOGIES, INC.
	By:	/s/ Maria Zannes
	Name:	Maria Zannes
	Title:	President and Chief Executive Officer

-3-

FAQ

What did BIAF announce in its 8-K?

The company announced Australian Patent Office acceptance of patent application AU 2019253111 for a system and method to determine lung health.

Which technologies are covered by the accepted patent for BIAF?

It covers methods using flow cytometry with fluorescent probes and molecular tags targeting specific cell types.

What conditions does the BIAF patent aim to address?

It targets detection of cellular and molecular signatures of multiple lung diseases.

What is the title of BIAF’s accepted Australian patent application?

The title is “System and Method for Determining Lung Health.”

When did BIAF announce the Australian patent acceptance?

The announcement was made on October 28, 2025.

Where can investors find more details on BIAF’s patent news?

See the company’s press release attached as Exhibit 99.1.